ClinicalTrials.gg
CompletedNCT02710500Updated May 13, 2021

rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies

A Phase 1 interventional study of rAAVrh74.MHCK7.DYSF.DV in Dysferlinopathy, sponsored by Sarepta Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Muscular Dystrophies, Limb-Girdle · United States.

Enrollment
15th of 17
2 · median 11
Started
2016
with 1 other
Phase 1
5 of 30
none open now
Registered
11th of 30
by date
Lead sponsor
8 of 30
Sarepta Therapeutics, Inc.

Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2016, is one of 5 in phase 1, and was the 11th registered.

Muscular Dystrophies, Limb-Girdle

47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.

Browse Muscular Dystrophies, Limb-Girdle studies →

Open to participants now

3 of the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Muscular Dystrophies, Limb-Girdle studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, or all of them as a file.
02

Study summary

The proposed clinical trial is a double-blind, randomized controlled study with direct intramuscular injection of rAAVrh.74.MHCK7.DYSF.DV gene vector to the extensor digitorum brevis muscle (EDB). Two cohorts of subjects with dysferlin deficiency, each with proven mutations will undergo gene transfer. A minimum of three subjects will be enrolled into each cohort.

Read the detailed description

This is a phase I safety and tolerability study with a direct intramuscular injection of rAAVrh.74.MHCK7.DYSF.DV transferred to the extensor digitorum brevis muscle (EDB). The study is designed as a randomized, controlled, dose escalation trial with one EDB receiving the rAAVrh.74.MHCK7.DYSF.DV and the other side receiving saline alone. It will follow the previously safe and effective IM gene transfer to EDB for LGMD2D.2, 3 The first cohort, inclusive of three Dysferlinopathy subjects, will receive a gene transfer total dose of 2 x 10\^12 vector genomes. Muscle biopsies will be performed at Day 45 (two subjects) and Day 90 (one subject). If there are no safety concerns, three additional subjects will be enrolled and receive an escalated dose at 6 X 10\^12 vg (total dose). Muscle biopsies in the second cohort will be performed at Day 90 (one subject) and Day 180 (two subjects). This protocol design gives us a maximum period of observation ranging from 6 weeks to 6 months to capture both transient and delayed gene expression, and to recognize sustained expression.

03

Conditions studied

  • Dysferlinopathy

Keywords

  • LGMD2B
  • Limb Girdle Muscular Dystrophy
  • Miyoshi
  • Gene Transfer
  • Dysferlin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be Non-ambulant (cannot walk 10 meters in ≤ 30 sec) and age 18 years or older
  • Established mutations of the dysferlin gene on both alleles
  • Impaired muscle function but with sufficient muscle preservation to ensure muscle transfection based on magnetic resonance image of the EDB showing sufficient muscle preservation to permit transfection
  • Willingness of sexually active subjects with reproductive capacity to practice reliable method of (If appropriate), during the first six months after gene transfer (females) or until two negative sperm samples are obtained post gene transfer (males).

Exclusion criteria

Exclusion Criteria:

  • Active viral infection based on clinical observations or serological evidence of , or Hepatitis A, B or C infection
  • The presence of a Dysferlin mutations without weakness or loss of function
  • Symptoms or signs of cardiomyopathy, including:
  • Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs
  • Echocardiogram with below 40%
  • Diagnosis of (or ongoing treatment for) an disease
  • Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥ 20.0 K/µL) or an \< 1.5K/µL
  • Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer
  • Pregnancy
  • AAVrh74 or AAV8 binding antibody titers > 1:50 as determined by ELISA immunoassay
  • Abnormal laboratory values in the range in the table below, based upon normal values in the Nationwide Children's Hospital Laboratory: GGT, Total , Cystatine, , White Blood Cells
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Low Dose)

    Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 2 x 10\^12 in one muscle. Intervention Drug: rAAVrh.MHCK7.DYSF.DV

    Drug: rAAVrh74.MHCK7.DYSF.DV

  • Experimental
    Cohort 2 (High Dose)

    Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 6 x 10\^12 vg in one muscle. Intervention Drug: rAAVrh74.MHCK7.DYSF.DV

    Drug: rAAVrh74.MHCK7.DYSF.DV

Interventions

  • DrugrAAVrh74.MHCK7.DYSF.DV

    Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.

06

What researchers measure

Primary outcomes

  1. Determination of safety based on the development of unacceptable toxicity

    Defined as the occurrence of any one Grade III or higher, unanticipated, treatment-related toxicity

    Time frame: 2 Years

Secondary outcomes

  1. Number of participants showing dysferlin protein expression in muscle tissue

    More than 3 fold increase in dysferlin protein expression in muscle compared to control side by western blot or more than 30% increase in dysferlin-expressing fibers Dysferlin protein expression as demonstrated with N -terminal anti-dysferlin antibodies will be quantified using BioQuant

    Time frame: 2 Years

  2. Leukocyte marker counts including CD45, CD3, CD4, CD8, and MAC 387.

    Number of CD4+ cells/ mm2 area; Number of CD8+ cells/ mm2 area; Number of muscle fibers expressing MHCI staining / mm2 area; Number of muscle fibers expressing MHCII staining / mm2 area

    Time frame: 2 Years

  3. Binding antibodies counts and ELISpot counts to both rAAVrh74 capsid and dysferlin protein.

    AAVrh74 or AAV8 binding antibody titers \> 1:50 as determined by ELISA immunoassay

    Time frame: 2 Years

  4. Number of inflammatory cells in muscle

    Number of inflammatory cells per mm2 area

    Time frame: 2 Years

07

Study locations

1 site
  • Nationwide Children's Hosptial
    Columbus, Ohio 43205, United States
08

References and documents

Publications

  • Sondergaard PC, Griffin DA, Pozsgai ER, Johnson RW, Grose WE, Heller KN, Shontz KM, Montgomery CL, Liu J, Clark KR, Sahenk Z, Mendell JR, Rodino-Klapac LR. AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models. Ann Clin Transl Neurol. 2015 Mar;2(3):256-70. doi: 10.1002/acn3.172. Epub 2015 Jan 20. PubMed 25815352 ↗
  • Grose WE, Clark KR, Griffin D, Malik V, Shontz KM, Montgomery CL, Lewis S, Brown RH Jr, Janssen PM, Mendell JR, Rodino-Klapac LR. Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One. 2012;7(6):e39233. doi: 10.1371/journal.pone.0039233. Epub 2012 Jun 15. PubMed 22720081 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Jul 2019 and a completion of Jul 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2016
First posted
Mar 16, 2016
Start
Mar 2016
Primary completionActual
Jul 2019
CompletionActual
Jul 2019
Last update
May 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02710500
Responsible party
Sponsor
First posted
Mar 16, 2016
Start date
Mar 2016
Primary completion
Jul 2019
Completion
Jul 2019
Last update
May 13, 2021

Study contacts

Jerry R Mendell, MD
principal investigator · Director, Center for Gene Therapy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion